Details of the Drug Combination

General Information of Drug Combination (ID: DCM01BZ)

• Drug Combination Name: Metaxalone + BIO-300
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  Metaxalone (DMXLZP6): Small molecular drug
  BIO-300 (DMJ7NVI): N.A.
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 3.13
  Bliss Independence Score: 3.13
  Loewe Additivity Score: 3.71
  LHighest Single Agent (HSA) Score: 3.71

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7609).
• [3] Clinical pipeline report, company report or official report of Humanetics.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)